{"analytics_identifier":null,"base_path":"/government/news/government-invests-in-global-partnership-to-treat-gonorrhoea","content_id":"39b5c858-52da-44c4-9e90-268891121eef","document_type":"news_story","first_published_at":"2019-10-28T13:57:47.000+00:00","locale":"en","phase":"live","public_updated_at":"2019-10-29T11:41:37.000+00:00","publishing_app":"content-publisher","publishing_scheduled_at":null,"rendering_app":"government-frontend","scheduled_publishing_delay_seconds":null,"schema_name":"news_article","title":"Government invests in global partnership to treat gonorrhoea","updated_at":"2019-10-29T11:41:37.961Z","withdrawn_notice":{},"publishing_request_id":"13683-1572349296.403-10.3.3.1-1747","links":{"taxons":[{"api_path":"/api/content/health-and-social-care/medicines-medical-devices-blood","base_path":"/health-and-social-care/medicines-medical-devices-blood","content_id":"cebc01ee-f70a-4397-a552-622e10b62508","document_type":"taxon","locale":"en","public_updated_at":"2019-02-06T16:16:55Z","schema_name":"taxon","title":"Medicines, medical devices","withdrawn":false,"description":"","details":{"internal_name":"Medicines and medical devices [T] (level 2, health theme)","notes_for_editors":"","visible_to_departmental_editors":false},"phase":"live","links":{"parent_taxons":[{"api_path":"/api/content/health-and-social-care","base_path":"/health-and-social-care","content_id":"8124ead8-8ebc-4faf-88ad-dd5cbcc92ba8","document_type":"taxon","locale":"en","public_updated_at":"2018-09-16T20:30:51Z","schema_name":"taxon","title":"Health and social care","withdrawn":false,"description":"","details":{"internal_name":"Health and social care","notes_for_editors":"","visible_to_departmental_editors":true},"phase":"live","links":{"root_taxon":[{"api_path":"/api/content/","base_path":"/","content_id":"f3bbdec2-0e62-4520-a7fd-6ffd5d36e03a","document_type":"homepage","locale":"en","public_updated_at":"2019-06-21T11:52:37Z","schema_name":"homepage","title":"GOV.UK homepage","withdrawn":false,"links":{},"api_url":"https://www.gov.uk/api/content/","web_url":"https://www.gov.uk/"}]},"api_url":"https://www.gov.uk/api/content/health-and-social-care","web_url":"https://www.gov.uk/health-and-social-care"}]},"api_url":"https://www.gov.uk/api/content/health-and-social-care/medicines-medical-devices-blood","web_url":"https://www.gov.uk/health-and-social-care/medicines-medical-devices-blood"},{"api_path":"/api/content/health-and-social-care/research-and-innovation-in-health-and-social-care","base_path":"/health-and-social-care/research-and-innovation-in-health-and-social-care","content_id":"2eb09bb6-b069-4604-a55a-08e6cd46d257","document_type":"taxon","locale":"en","public_updated_at":"2019-02-06T08:18:39Z","schema_name":"taxon","title":"Research and innovation in health and social care","withdrawn":false,"description":"","details":{"internal_name":"Research and innovation in health and social care [P] (level 3, health theme)","notes_for_editors":"","visible_to_departmental_editors":false},"phase":"live","links":{"parent_taxons":[{"api_path":"/api/content/health-and-social-care","base_path":"/health-and-social-care","content_id":"8124ead8-8ebc-4faf-88ad-dd5cbcc92ba8","document_type":"taxon","locale":"en","public_updated_at":"2018-09-16T20:30:51Z","schema_name":"taxon","title":"Health and social care","withdrawn":false,"description":"","details":{"internal_name":"Health and social care","notes_for_editors":"","visible_to_departmental_editors":true},"phase":"live","links":{"root_taxon":[{"api_path":"/api/content/","base_path":"/","content_id":"f3bbdec2-0e62-4520-a7fd-6ffd5d36e03a","document_type":"homepage","locale":"en","public_updated_at":"2019-06-21T11:52:37Z","schema_name":"homepage","title":"GOV.UK homepage","withdrawn":false,"links":{},"api_url":"https://www.gov.uk/api/content/","web_url":"https://www.gov.uk/"}]},"api_url":"https://www.gov.uk/api/content/health-and-social-care","web_url":"https://www.gov.uk/health-and-social-care"}]},"api_url":"https://www.gov.uk/api/content/health-and-social-care/research-and-innovation-in-health-and-social-care","web_url":"https://www.gov.uk/health-and-social-care/research-and-innovation-in-health-and-social-care"},{"api_path":"/api/content/health-and-social-care/antimicrobial-resistance","base_path":"/health-and-social-care/antimicrobial-resistance","content_id":"645d4bd6-84a2-49e0-bc38-f0d5459f583e","document_type":"taxon","locale":"en","public_updated_at":"2018-11-21T16:26:43Z","schema_name":"taxon","title":"Antimicrobial resistance (AMR)","withdrawn":false,"description":"","details":{"internal_name":"Antimicrobial resistance (AMR)","notes_for_editors":"","visible_to_departmental_editors":false},"phase":"live","links":{"parent_taxons":[{"api_path":"/api/content/health-and-social-care/health-protection","base_path":"/health-and-social-care/health-protection","content_id":"30ba2d05-d0d6-4978-a5d6-707511894111","document_type":"taxon","locale":"en","public_updated_at":"2019-03-11T14:19:39Z","schema_name":"taxon","title":"Health protection","withdrawn":false,"description":"","details":{"internal_name":"Health protection","notes_for_editors":"","visible_to_departmental_editors":false},"phase":"live","links":{"parent_taxons":[{"api_path":"/api/content/health-and-social-care/public-health","base_path":"/health-and-social-care/public-health","content_id":"d6a4884e-769d-4b81-8ba5-b64394362d92","document_type":"taxon","locale":"en","public_updated_at":"2018-09-17T15:15:14Z","schema_name":"taxon","title":"Public health","withdrawn":false,"description":"","details":{"internal_name":"Public health","notes_for_editors":"","visible_to_departmental_editors":false},"phase":"live","links":{"parent_taxons":[{"api_path":"/api/content/health-and-social-care","base_path":"/health-and-social-care","content_id":"8124ead8-8ebc-4faf-88ad-dd5cbcc92ba8","document_type":"taxon","locale":"en","public_updated_at":"2018-09-16T20:30:51Z","schema_name":"taxon","title":"Health and social care","withdrawn":false,"description":"","details":{"internal_name":"Health and social care","notes_for_editors":"","visible_to_departmental_editors":true},"phase":"live","links":{"root_taxon":[{"api_path":"/api/content/","base_path":"/","content_id":"f3bbdec2-0e62-4520-a7fd-6ffd5d36e03a","document_type":"homepage","locale":"en","public_updated_at":"2019-06-21T11:52:37Z","schema_name":"homepage","title":"GOV.UK homepage","withdrawn":false,"links":{},"api_url":"https://www.gov.uk/api/content/","web_url":"https://www.gov.uk/"}]},"api_url":"https://www.gov.uk/api/content/health-and-social-care","web_url":"https://www.gov.uk/health-and-social-care"}]},"api_url":"https://www.gov.uk/api/content/health-and-social-care/public-health","web_url":"https://www.gov.uk/health-and-social-care/public-health"}]},"api_url":"https://www.gov.uk/api/content/health-and-social-care/health-protection","web_url":"https://www.gov.uk/health-and-social-care/health-protection"}]},"api_url":"https://www.gov.uk/api/content/health-and-social-care/antimicrobial-resistance","web_url":"https://www.gov.uk/health-and-social-care/antimicrobial-resistance"}],"organisations":[{"analytics_identifier":"D12","api_path":"/api/content/government/organisations/department-of-health-and-social-care","base_path":"/government/organisations/department-of-health-and-social-care","content_id":"7cd6bf12-bbe9-4118-8523-f927b0442156","document_type":"organisation","locale":"en","schema_name":"organisation","title":"Department of Health and Social Care","withdrawn":false,"details":{"logo":{"formatted_title":"Department<br/>of Health &amp;<br/>Social Care","crest":"single-identity"},"brand":"department-of-health","default_news_image":{"url":"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/default_news_organisation_image_data/file/235/s300_Default_image_39_Victoria_street_department_of_health.jpg","high_resolution_url":"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/default_news_organisation_image_data/file/235/s960_Default_image_39_Victoria_street_department_of_health.jpg"}},"links":{},"api_url":"https://www.gov.uk/api/content/government/organisations/department-of-health-and-social-care","web_url":"https://www.gov.uk/government/organisations/department-of-health-and-social-care"}],"primary_publishing_organisation":[{"analytics_identifier":"D12","api_path":"/api/content/government/organisations/department-of-health-and-social-care","base_path":"/government/organisations/department-of-health-and-social-care","content_id":"7cd6bf12-bbe9-4118-8523-f927b0442156","document_type":"organisation","locale":"en","schema_name":"organisation","title":"Department of Health and Social Care","withdrawn":false,"details":{"logo":{"formatted_title":"Department<br/>of Health &amp;<br/>Social Care","crest":"single-identity"},"brand":"department-of-health","default_news_image":{"url":"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/default_news_organisation_image_data/file/235/s300_Default_image_39_Victoria_street_department_of_health.jpg","high_resolution_url":"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/default_news_organisation_image_data/file/235/s960_Default_image_39_Victoria_street_department_of_health.jpg"}},"links":{},"api_url":"https://www.gov.uk/api/content/government/organisations/department-of-health-and-social-care","web_url":"https://www.gov.uk/government/organisations/department-of-health-and-social-care"}],"available_translations":[{"title":"Government invests in global partnership to treat gonorrhoea","public_updated_at":"2019-10-29T11:41:37Z","document_type":"news_story","schema_name":"news_article","base_path":"/government/news/government-invests-in-global-partnership-to-treat-gonorrhoea","api_path":"/api/content/government/news/government-invests-in-global-partnership-to-treat-gonorrhoea","withdrawn":false,"content_id":"39b5c858-52da-44c4-9e90-268891121eef","locale":"en","api_url":"https://www.gov.uk/api/content/government/news/government-invests-in-global-partnership-to-treat-gonorrhoea","web_url":"https://www.gov.uk/government/news/government-invests-in-global-partnership-to-treat-gonorrhoea","links":{}}]},"description":"The £3.5 million investment will help develop new treatments for gonorrhoea and make them available to low- and middle-income countries.","details":{"body":"<p>The investment is part of a continued partnership with the Global Antimicrobial Resistance Innovation Fund (<abbr title=\"the Global Antimicrobial Resistance Innovation Fund\">GAMRIF</abbr>) and the <a rel=\"external\" href=\"https://www.gardp.org/\">Global Antibiotic Research and Development Partnership (<abbr title=\"the Global Antibiotic Research and Development Partnership\">GARDP</abbr>)</a>.</p>\n\n<p>The investment will:</p>\n\n<ul>\n  <li>\n    <p>enable global access to treatment, including in low- and middle-income countries where the burden of antimicrobial resistance (<abbr title=\"antimicrobial resistance\">AMR</abbr>) is greatest</p>\n  </li>\n  <li>\n    <p>fund <abbr title=\"the Global Antibiotic Research and Development Partnership\">GARDP</abbr>’s development of oral antibiotic zoliflodacin, which is now in the last stage of clinical trials before reaching the market</p>\n  </li>\n</ul>\n\n<p>Zoliflodacin is one of the few antibiotics in development to specifically treat gonorrhoea and is significant as treatments for gonorrhoea are becoming less effective. </p>\n\n<p>There have been cases of gonorrhoea developing resistance to recommended treatments, including in the UK.</p>\n\n<p>Gonorrhoea is among the most common sexually-transmitted infections (<abbr title=\"sexually-transmitted infections\">STIs</abbr>), with an estimated 87 million new cases globally every year.</p>\n\n<p>The <abbr title=\"sexually-transmitted infection\">STI</abbr> can have severe consequences on public health and, when left untreated, serious consequences for reproductive health as well as increased risk of transmission of HIV and other <abbr title=\"sexually-transmitted infections\">STIs</abbr>.</p>\n\n<p>Women, and marginalised and vulnerable groups are disproportionately affected.</p>\n\n<p>Gonorrhoea has been identified as posing a significant threat to global health by the World Health Organization (WHO). There is now an urgent need for new treatment options, particularly for people in developing countries.</p>\n\n<p>Addressing drug-resistant infections is critical to achieving the <a rel=\"external\" href=\"https://www.un.org/sustainabledevelopment/sustainable-development-goals/\">UN’s sustainable development goals</a>, particularly the target for good health and wellbeing for all. </p>\n\n<p><abbr title=\"the Global Antibiotic Research and Development Partnership\">GARDP</abbr> will now start pharmaceutical development activities for zoliflodacin, and will develop a new strategy for access and appropriate use in low- and middle-income countries that have a high number of cases of gonorrhoea.</p>\n\n<p><a rel=\"external\" href=\"https://www.gardp.org/2019/news-resources/press-releases/gardp-announces-5by25-goal-antibiotic-resistant-infections/\"><abbr title=\"the Global Antibiotic Research and Development Partnership\">GARDP</abbr> plans to develop 5 new treatments for bacterial infections by 2025.</a></p>\n\n<p>Minister for Innovation, Nicola Blackwood, said:</p>\n\n<blockquote>\n  <p>The UK is a global leader in tackling antimicrobial resistance, a threat that is posing serious risks to health and the global economy, as well as killing hundreds of thousands of people around the world each year.</p>\n\n  <p class=\"last-child\">It is vital to fund new antibiotic research and development to tackle <abbr title=\"antimicrobial resistance\">AMR</abbr> and this innovative project will develop solutions to treat the global rise of gonorrhoea and improve the quality of people’s lives.</p>\n</blockquote>\n\n<p>Dr Manica Balasegaram, Executive Director of <abbr title=\"the Global Antibiotic Research and Development Partnership\">GARDP</abbr>, said:</p>\n\n<blockquote>\n  <p>We are excited to unveil our new strategy, 5 BY 25, outlining <abbr title=\"the Global Antibiotic Research and Development Partnership\">GARDP</abbr>’s ambition to accelerate the development of 5 new treatments by 2025.</p>\n\n  <p>The recent initiation of the phase 3 trial of zoliflodacin is an important milestone towards bringing one of our 5 treatments a step closer to patients by 2025.</p>\n\n  <p class=\"last-child\">The global nature of the trial, across 4 continents, represents our commitment to ensuring this treatment is available to anyone in need, wherever they live.</p>\n</blockquote>\n\n","image":{"high_resolution_url":"https://assets.publishing.service.gov.uk/media/5db6eeaded915d1d001e605d/doctor-putting-pills-into-boxes.jpg","url":"https://assets.publishing.service.gov.uk/media/5db6eeace5274a4aa29e3c0c/doctor-putting-pills-into-boxes.jpg","alt_text":"Close up of hands in surgical gloves putting pills into boxes","caption":"","credit":""},"change_history":[{"note":"First published.","public_timestamp":"2019-10-28T13:50:26.905Z"},{"note":"The following information has been added to paragraph 1: the Global Antimicrobial Resistance Innovation Fund (GAMRIF) are also part of the continued partnership with the government.","public_timestamp":"2019-10-29T10:58:32.660Z"}]},"document_status":"draft","created_by":"Wolfgang Güllick","last_updated_by":"Hazel Findlay","political":true,"government":{"title":"2015 Conservative government","slug":"2015-conservative-government","start_date":"2015-05-07T23:00:00.000Z","end_date":"","current":true}}